Identification of predictive factors for early relapse in patients with unresectable stage III non‐small cell lung cancer receiving consolidation durvalumab after concurrent chemoradiation therapy

Identification of predictive factors for early relapse in patients with unresectable stage III non‐small cell lung cancer receiving consolidation durvalumab after concurrent chemoradiation therapy

Abstract Background Patients with locally advanced, unresectable, non‐small cell lung cancer (NSCLC) receiving definitive concurrent chemoradiation therapy (CCRT) benefit from durvalumab consolidation therapy. However, predictive factors for early relapse during durvalumab maintenance have not yet b...

Full description

Bibliographic Details
Main Authors: Jung Hyun Nam, Chang Dong Yeo, Chan Kwon Park, Sung Kyoung Kim, Ju Sang Kim, Yong Hyun Kim, Jin Woo Kim, Seung Joon Kim, Sang Haak Lee, Hye Seon Kang
Format: Article
Language:English
Published: Wiley 2023-09-01
Series:Thoracic Cancer
Subjects:
chemoradiotherapy
durvalumab
non‐small cell lung cancer
recurrence
Online Access:https://doi.org/10.1111/1759-7714.15050

Internet

https://doi.org/10.1111/1759-7714.15050

Similar Items